TScan Therapeutics (TCRX) Retained Earnings (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Retained Earnings data on file, last reported at -$533.5 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 13338100.0% year-over-year to -$533.5 million in Q1 2026; TTM through Mar 2026 was -$533.5 million, a 13338100.0% decrease from a year earlier, with the FY2025 full-year figure at -$504.9 million, down 34.6% from the prior year.
• Retained Earnings for Q1 2026 stood at -$533.5 million, down from -$504.9 million in the prior quarter.
• Over the last five years, Retained Earnings for TCRX reached as high as -$4000.0 in Q1 2025 and fell as low as -$533.5 million in Q1 2026.
• Historically, Retained Earnings has averaged -$274.1 million across 5 years, with a median of -$247.6 million in 2023.
• Across the five-year window, Retained Earnings jumped 100.0% in 2025 and plunged 13338100.0% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$158.4 million in 2022, then tumbled by 56.33% to -$247.6 million in 2023, then plunged by 51.49% to -$375.1 million in 2024, then slumped by 34.6% to -$504.9 million in 2025, then retreated by 5.68% to -$533.5 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$533.5 million in Q1 2026, -$504.9 million in Q4 2025, and -$481.9 million in Q3 2025.